Literature DB >> 7953986

Carboxyterminal propeptide of type I procollagen in osteomalacia.

F Li1, J Iqbal, W Wassif, I Kaddam, C Moniz.   

Abstract

Carboxyterminal propeptide of type I procollagen (PICP) was measured in sera from 25 patients with osteomalacia due to privational vitamin D deficiency. The mean value of serum PICP was significantly raised in patients with osteomalacia compared with 40 normal subjects (mean +/- SD, 161 +/- 82 ng/ml and 113 +/- 31 ng/ml, respectively; P = 0.01). The raised serum PICP reflected the accelerated bone turnover in this condition as did the elevated serum total alkaline phosphatase (ALP), but the variation in values of serum PICP noted in individual patients may reflect the different stages of osteomalacia. The normalization of serum PICP and ALP, indicating a healing process of the bone disorder, needed longer time of vitamin D and calcium therapy. In contrast, adjusted serum calcium and inorganic phosphate (IP) responded and normalized rapidly. Serum PICP and total ALP appeared to behave differently in the disease and in its response to vitamin D therapy suggesting that these two markers may represent different functions of osteoblasts in osteomalacia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7953986     DOI: 10.1007/BF00297181

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  16 in total

Review 1.  Osteomalacia.

Authors:  J A Eisman
Journal:  Baillieres Clin Endocrinol Metab       Date:  1988-02

2.  The effect of the menopause and hormone replacement therapy on serum carboxyterminal propeptide of type I collagen.

Authors:  C Hassager; G Fabbri-Mabelli; C Christiansen
Journal:  Osteoporos Int       Date:  1993-01       Impact factor: 4.507

3.  Correcting the calcium.

Authors: 
Journal:  Br Med J       Date:  1977-03-05

4.  Osteopenia and osteomalacia after gastrectomy: interrelations between biochemical markers of bone remodelling, vitamin D metabolites, and bone histomorphometry.

Authors:  S Bisballe; E F Eriksen; F Melsen; L Mosekilde; O H Sørensen; I Hessov
Journal:  Gut       Date:  1991-11       Impact factor: 23.059

5.  Serum osteocalcin in the treatment of inherited rickets with 1,25-dihydroxyvitamin D3.

Authors:  C M Gundberg; D E Cole; J B Lian; T M Reade; P M Gallop
Journal:  J Clin Endocrinol Metab       Date:  1983-05       Impact factor: 5.958

6.  The carboxy-terminal propeptide of type I procollagen in serum as a marker of bone formation: the effect of nandrolone decanoate and female sex hormones.

Authors:  C Hassager; L T Jensen; J S Johansen; B J Riis; J Melkko; J Pødenphant; L Risteli; C Christiansen; J Risteli
Journal:  Metabolism       Date:  1991-02       Impact factor: 8.694

7.  Serum levels of type I and III procollagen fragments in Paget's disease of bone.

Authors:  L S Simon; S M Krane; P D Wortman; I M Krane; K L Kovitz
Journal:  J Clin Endocrinol Metab       Date:  1984-01       Impact factor: 5.958

8.  Concurrent assays of circulating bone Gla-protein and bone alkaline phosphatase: effects of sex, age, and metabolic bone disease.

Authors:  R J Duda; J F O'Brien; J A Katzmann; J M Peterson; K G Mann; B L Riggs
Journal:  J Clin Endocrinol Metab       Date:  1988-05       Impact factor: 5.958

9.  Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with Iliac bone formation rates and comparison with total alkaline phosphatase.

Authors:  A M Parfitt; L S Simon; A R Villanueva; S M Krane
Journal:  J Bone Miner Res       Date:  1987-10       Impact factor: 6.741

10.  Serum concentrations of procollagen I C-terminal propeptide, osteocalcin and insulin-like growth factor-I in patients with non-lethal osteogenesis imperfecta.

Authors:  R E Brenner; B Schiller; U Vetter; J Ittner; W M Teller
Journal:  Acta Paediatr       Date:  1993-09       Impact factor: 2.299

View more
  3 in total

1.  High bone mineral density in pycnodysostotic patients with a novel mutation in the propeptide of cathepsin K.

Authors:  A F Schilling; C Mülhausen; W Lehmann; R Santer; T Schinke; J M Rueger; M Amling
Journal:  Osteoporos Int       Date:  2007-01-06       Impact factor: 4.507

2.  Collagenous and non-collagenous biochemical markers of bone metastases from prostate cancer.

Authors:  A Zafeirakis
Journal:  Hippokratia       Date:  2010-07       Impact factor: 0.471

3.  Early increase of bone resorption in patients with liver cirrhosis secondary to viral hepatitis.

Authors:  G R Corazza; F Trevisani; M Di Stefano; S De Notariis; G Veneto; L Cecchetti; L Minguzzi; G Gasbarrini; M Bernardi
Journal:  Dig Dis Sci       Date:  2000-07       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.